Join our daily newsletter At The Bell to receive exclusive market insights
- EMVision Medical Devices (EMV) activates stage two of the multi-site trial for its first-generation portable brain scanner
- Stage two will see EMV enrol 150 acute stroke and stroke-mimic patients across major medical centres in Australia
- The company announced it made improvements to its brain scanner after gaining insights from the stage one trial which involved 30 healthy volunteers
- New South Wales’ Liverpool Hospital will become the first site activated for stage two, followed by Royal Melbourne in June
- Shares in EMV last traded at $1.55 at 10:30 am AEST
EMVision Medical Devices (EMV) has activated stage two of the multi-site trial for its first-generation portable brain scanner.
The Brisbane-based company announced stage two would see it enrol 150 acute stroke and stroke-mimic patients across major stroke centres in Australia, including Liverpool Hospital in New South Wales, Royal Melbourne, and Princess Alexandra in Queensland.
It comes following the completion of stage one which included 30 healthy volunteers.
The company announced insights from stage one resulted in usability, workflow and technical improvements to its brain scanner.
“We have taken the technical and usability information from stage one and refined our device for stage two and although the modifications are not major, they will result in significant improvements in performance,” EMVision CEO Dr Ron Weinberger commented.
The Liverpool Hospital will become the first site activated for stage two, while the company is aiming to activate Royal Melbourne in June, followed by Princess Alexandra.
Shares in EMV last traded at $1.55 at 10:30 am AEST.
